BI 224436

BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.

Product information

CAS Number: 1155419-89-8

Molecular Weight: 442.51

Formula: C27H26N2O4

Synonym:

BI-224436

Chemical Name: 2-(tert-butoxy)-2-(2-methyl-4-{2-oxa-8-azatricyclo[7.3.1.0⁵,¹³]trideca-1(12),5(13),6,8,10-pentaen-10-yl}quinolin-3-yl)acetic acid

Smiles: CC1=NC2=CC=CC=C2C(=C1C(OC(C)(C)C)C(O)=O)C1=CC=C2OCCC3C=CN=C1C2=3

InChiKey: MIXIIJCBELCMCZ-UHFFFAOYSA-N

InChi: InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

Products are for research use only. Not for human use.